
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity has reported a significant growth of over 100% in its POC and formulary offerings, indicating strong demand and successful expansion in its service portfolio. The company's stock has shown resilience with a modest increase of 3.2% since September 8, suggesting positive market sentiment. Furthermore, the guidance for the second quarter appears attainable, with indications of potential upside, which positions Doximity favorably for future growth.
Bears say
Doximity Inc. is experiencing negative financial outlooks primarily due to the uncertain economic environment, which has prompted its pharmaceutical clients to issue downward revisions for fiscal years 2023 and 2024. Additionally, the company's shares are perceived as expensive compared to its software peers, making them susceptible to volatility should performance expectations not be met. Lastly, heightened scrutiny on Doximity's financial results intensifies the potential for disappointment if the company fails to deliver positive outcomes or raise guidance.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares